Pitt B(1), Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. Rossignol P(1), Ménard J, Fay R. Eur J Heart Fail. May;8(3) Epub Feb Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular.

Author: Nikojinn Brasar
Country: Croatia
Language: English (Spanish)
Genre: Marketing
Published (Last): 3 July 2014
Pages: 323
PDF File Size: 2.1 Mb
ePub File Size: 17.30 Mb
ISBN: 653-5-54340-920-1
Downloads: 37138
Price: Free* [*Free Regsitration Required]
Uploader: Tele

This good tolerance was obtained with The secondary endpoint of all cause mortality was met by View large Download slide.

Can we trust observational data for clinical decision-making? Norfolk, UKF.

Aldosterone and long-term outcome after myocardial infarction: See page for the editorial comment on this article doi: Latest Most Read Most Cited Transcatheter aortic valve replacement in patients with concomitant mitral stenosis.

The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Caution is warranted when warfarin is dosed near the upper limit of therapeutic range.

There was a problem providing the content you requested

We enrolled low-risk subjects as eplerenone is already licensed for use in the higher risk patients with HF post AMI. More on this topic Association between C-reactive protein and generalized anxiety disorder in stable coronary heart disease patients.


This risk may be wplerenone increased when co-morbidity associated with increased systemic exposure is also present, in particular mild-to-moderate hepatic impairment. Heart failure was adjudicated by a clinical endpoint committee.

The trial was monitored by an independent data and safety monitoring committee. The aim of the present study was to investigate the safety and efficacy of eplerenonf early initiation of eplerenone, within the first 24 h of symptom onset when acute reperfusion is delivered to patients presenting STEMI without known heart failure.

Musculoskeletal and connective tissue disorders. Lithium, cyclosporin, tacrolimus should be avoided during treatment with eplerenone see section 4.

To email a medicine you must sign up and log in. Co-administration of eplerenone with strong CYP3A4 inducers is not recommended see section 4. Endpoints were adjudicated by an independent endpoint adjudication committee see Appendix. Eplerenone dosing should therefore not exceed 25 mg when mild to moderate inhibitors of CYP3A4 are co-administered with eplerenone see section 4.

EPHESUS – Wiki Journal Club

Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: These results confirm the blockade of the mineralocorticoid receptor in these populations. If this combination appears necessary, lithium plasma concentrations should be monitored see section 4.

B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Eplerenone prevents the binding of aldosterone, a key hormone in the renin-angiotensin-aldosterone-system RAASwhich is involved in the regulation of blood pressure and the pathophysiology of CV disease.


Eplerenone is not removed by haemodialysis. Comment in J Fam Pract. Data were collected, managed, and analysed by a clinical research organization, contracted by the sponsor, according to the protocol and a predefined statistical analysis plan.

A close monitoring of serum potassium and renal function is recommended, especially in patients at risk for impaired eplerenoe function, e. It should also be emphasized that there were no elhesus associated with the development of hyperkalaemia in patients randomized to eplerenone.

Eplerenone 50 mg film-coated tablets

Eplerenone has been shown to bind extensively to charcoal. Hyperkalaemia Consistent with its mechanism of action, hyperkalaemia may occur with eplerenone. Related articles in Web of Science Google Scholar. In dose-ranging studies of chronic heart failure NYHA classification II-IVthe addition of eplerenone to standard therapy resulted in expected dose-dependent increases in aldosterone. Creating certainty out of uncertainty.